Can CD366 Become the Next Key Target in Cancer Immunotherapy?

1. Concept

Immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4 have revolutionized cancer treatment, but limited response rates, drug resistance, and poor efficacy against "cold tumors" remain major challenges. CD366 (also known as TIM-3), an emerging negative immune checkpoint molecule, has attracted widespread attention for its unique role in tumor immune suppression. As a type I transmembrane glycoprotein, CD366 is widely expressed on immune cells such as exhausted T cells, regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and dendritic cells. By interacting with ligands like galectin-9 (Gal-9) and phosphatidylserine (PtdSer), it inhibits immune cell activation and promotes tumor immune escape. Targeting CD366 has emerged as a promising strategy to expand immunotherapy coverage and overcome resistance, making it a potential next-generation key target in cancer immunotherapy.

2. Research Frontiers

2.1 Structural and Distribution Characteristics of CD366

The human CD366 gene is located on chromosome 5q33.2, a region associated with immune-related diseases. Its structure includes a signal peptide, immunoglobulin-like domain, mucin-like region, transmembrane domain, and intracellular domain with conserved tyrosine phosphorylation sites—critical for signal transduction. Unlike other TIM family members, CD366’s intracellular tyrosine residues enable unique signaling cascades.

CD366 was initially identified on IFN-γ-secreting CD4+ Th1 and CD8+ cytotoxic T cells. It is also expressed on Tregs, monocytes/macrophages, dendritic cells, and MDSCs. Its ligands include PtdSer, Gal-9, HMGB1, and Ceacam-1, whose binding regulates immune responses—particularly in the tumor microenvironment.

2.2 The Role of CD366 in Tumor Immunity

CD366 mediates tumor immune suppression through multiple mechanisms:

• T cell regulation: Exhausted CD8+ T cells highly express CD366 in the tumor microenvironment. Gal-9 binding induces intracellular tyrosine phosphorylation (Tyr256, Tyr263), releasing Bat3 and inactive Lck to suppress T cell effector functions. CD366+ Tregs secrete immunosuppressive factors (IL-10, perforin, granzymes), enhancing the suppressive microenvironment.
• Myeloid cell modulation: CD366+ T cells promote MDSC proliferation via Gal-9, suppressing local anti-tumor immunity. Tumor-associated dendritic cells (TADCs) upregulate CD366, interfering with DNA recognition and presentation of necrotic tumor cells, disrupting innate-adaptive immune crosstalk.

2.3 Development Progress of CD366 Inhibitors

No CD366 inhibitors are approved, but preclinical and clinical research is advancing rapidly:

• Drug types: Monoclonal antibodies, combination therapies, and bispecific antibodies targeting CD366-ligand interactions (e.g., Gal-9).
• Unique advantages: CD366 signaling does not rely on ITIM motifs, offering higher specificity and less interference with normal immunity compared to PD-1/CTLA-4.
• Combination potential: Preclinical studies show CD366 upregulation in PD-1 inhibitor-resistant models. Combined anti-CD366 + anti-PD-1 therapy enhances T cell proliferation, IFN-γ secretion, reverses T cell exhaustion, and prolongs survival.
• Clinical trials: Ongoing evaluations of monotherapies and combinations with PD-1/PD-L1 inhibitors to overcome resistance and improve response rates.

2.4 Future Outlook for CD366-Targeted Therapy

CD366’s selective expression in tumors and role in immune suppression make it a promising target. Future research will focus on:

• Elucidating synergistic mechanisms with PD-1/CTLA-4 to design individualized combination regimens.
• Developing high-affinity, specific CD366 antibodies to optimize target engagement.
• Exploring biomarkers to identify patients most likely to benefit from CD366-targeted therapy.

3. Research Significance

CD366-targeted therapy holds profound scientific and clinical significance:

• Scientific value: Expands understanding of immune checkpoint biology, revealing novel mechanisms of tumor immune escape and T cell exhaustion.
• Clinical value: Addresses unmet needs in immunotherapy-resistant patients and "cold tumors," offering new options for those unresponsive to PD-1/CTLA-4 inhibitors. Combination strategies have the potential to improve overall response rates and patient survival.

4. Related Mechanisms, Research Methods, and Product Applications

4.1 Core Mechanisms of CD366-Mediated Tumor Immune Suppression

CD366 drives immune escape through two key pathways:

1. T cell exhaustion: Ligand binding (e.g., Gal-9) triggers intracellular tyrosine phosphorylation, suppressing T cell proliferation, cytokine secretion, and cytotoxicity.
2. Suppressive microenvironment amplification: Promotes Treg immunosuppressive function and MDSC expansion, inhibiting anti-tumor immune cell infiltration and activation.

4.2 Key Research Methods

Studying CD366 involves preclinical and clinical approaches:

• Expression analysis: Flow cytometry, immunohistochemistry, and qPCR to detect CD366 on immune cells and tumor tissues.
• Functional assays: In vitro T cell proliferation/cytokine secretion assays to evaluate CD366 inhibition effects.
• Preclinical models: Syngeneic tumor models to test CD366 inhibitor monotherapy and combination with PD-1/PD-L1 inhibitors.
• Clinical trials: Assessing safety, efficacy, and pharmacokinetics of CD366 inhibitors in cancer patients.

4.3 Product Applications: ANT BIO PTE. LTD.’s CD366 Antibodies

ANT BIO PTE. LTD.’s STARTER brand offers high-performance CD366 (TIM-3) antibodies for preclinical research, supporting tumor immunology and immunotherapy studies:

Core Products

Core Product Advantages

• Specific blockade and high activity: Validated to block CD366-ligand interactions (Gal-9, CEACAM-1), reverse T cell exhaustion, and inhibit tumor growth in mouse models.
• Low endotoxin and in vivo compatibility: Endotoxin <1.0 EU/mg minimizes nonspecific immune activation, ensuring reliable preclinical results.
• Versatile applications: Suitable for flow cytometry, functional assays, and in vivo studies.

Key Application Scenarios

• Tumor immunotherapy research: Evaluating CD366 blockade on T cell exhaustion and tumor microenvironment remodeling.
• Combination therapy development: Exploring synergistic effects with PD-1/PD-L1 inhibitors in preclinical models.
• Chronic infection studies: Investigating CD366’s role in T cell exhaustion and viral persistence (e.g., LCMV, HIV models).
• Autoimmune disease research: Assessing CD366’s protective role in EAE, SLE models.

ANT BIO PTE. LTD. provides technical support, including efficacy data, dosing guidelines, and experimental design consultation.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative research tools and solutions. As a leader in life science reagents, we offer a comprehensive portfolio under three sub-brands: Absin (focused on general reagents and kits), Starter (specialized in antibodies), and UA (dedicated to recombinant proteins).

Our commitment to excellence is underpinned by advanced development platforms—including recombinant rabbit/mouse monoclonal antibody platforms, rapid monoclonal antibody development, recombinant protein expression systems (E. coli, CHO, HEK293, Insect Cells), One-Step ELISA Platforms, and PTM Pan-Modification Antibody Platforms—alongside rigorous quality control systems. We hold international certifications such as EU 98/79/EC, ISO9001, and ISO13485, ensuring our products meet the highest global standards.

Our mission is to accelerate scientific discovery, facilitate translational research, and contribute to the development of novel therapies for human health. By partnering with researchers in academia and biopharmaceutical companies worldwide, we strive to be a trusted collaborator in advancing life science research and addressing unmet medical needs.

6. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.